# Indaptus Therapeutics (INDP) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/INDP
## Company Profile
- Ticker: INDP
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 1.19 USD
- Market cap: 243470996.6 USD
- Last updated: 2026-08-11
## Business Overview
### Systemic Immunotherapy Platform
Indaptus Therapeutics develops systemically administered immunotherapies for cancer and viral disease. Its Decoy platform uses attenuated, inactivated, non-pathogenic Gram-negative bacteria to activate innate and adaptive immunity while seeking to maintain manageable systemic safety.
### Decoy Platform Rationale
The platform is based on the hypothesis that a combination of multi-target immune-activation signals can more effectively initiate antitumor and antiviral responses. Its design seeks to reduce intravenous toxicity while preserving broad stimulation of immune-cell populations.
### Strategic Review
The company is undergoing leadership changes and a reassessment of R&D priorities, including the Decoy platform’s clinical and regulatory feasibility, resource allocation, and potential partnerships. General strategic evaluation is not treated as a defined asset-level catalyst.
## Why The Stock Is Moving

As of Aug 11, 2026, INDP was little changed and closed at $1.19. No new same-company headline was identified in the current news window.

## Future Catalysts

- Indaptus’s catalysts are its immunotherapy platform and any update that shows the decoy-bacteria approach can still advance. The company needs clearer human proof.

## Recent News
- 2026-05-15 11:00 EST — [Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/INDP/indaptus-therapeutics-reports-first-quarter-2026-financial-results-and-provides--f6dfe577) — Source: Indaptus Therapeutics
- 2025-12-29 12:00 EST — [Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar](https://biopharmsignal.com/news/INDP/indaptus-enters-into-6-million-securities-purchase-agreement-with-investor-david-bcf9b890) — Source: Indaptus Therapeutics
- 2025-11-17 13:00 EST — [Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit](https://biopharmsignal.com/news/INDP/indaptus-therapeutics-chief-scientific-officer-dr-michael-newman-to-present-at-t-834c2934) — Source: Indaptus Therapeutics
- 2025-11-12 13:30 EST — [Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/INDP/indaptus-therapeutics-reports-third-quarter-2025-financial-results-and-provides--c94ae201) — Source: Indaptus Therapeutics
- 2025-09-04 20:01 EST — [Indaptus Therapeutics Provides Clinical Update](https://biopharmsignal.com/news/INDP/indaptus-therapeutics-provides-clinical-update-cc3b1325) — Source: Indaptus Therapeutics